A partial agonist for retinoid X receptor mitigates experimental colitis. (26th December 2018)
- Record Type:
- Journal Article
- Title:
- A partial agonist for retinoid X receptor mitigates experimental colitis. (26th December 2018)
- Main Title:
- A partial agonist for retinoid X receptor mitigates experimental colitis
- Authors:
- Onuki, Masayoshi
Watanabe, Masaki
Ishihara, Narumi
Suzuki, Koichiro
Takizawa, Kei
Hirota, Masato
Yamada, Takahiro
Egawa, Aiko
Shibahara, Osamu
Nishii, Midori
Fujihara, Michiko
Makishima, Makoto
Takahashi, Daisuke
Furusawa, Yukihiro
Kakuta, Hiroki
Hase, Koji - Abstract:
- Abstract: Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, is an intractable disease of the gastrointestinal tract. Multiple environmental factors, including food ingredients, have been implicated in the development of these diseases. For example, animal fat-rich diets are predisposing factors for ulcerative colitis, whereas n -3 unsaturated fatty acids such as docosahexaenoic acid (DHA) show protective effects in experimental colitis and are negatively correlated with the incidence of ulcerative colitis and Crohn's disease. Given that DHA exhibits agonistic activity on retinoid X receptor (RXR), activation of RXR could be a therapeutic strategy for IBD. However, conventional full RXR agonists are known to show considerable adverse effects. We therefore took advantage of a partial RXR agonist, CBt-PMN, to minimize the adverse effects, and evaluated its efficacy in dextran sodium sulfate-induced colitis. Administration of CBt-PMN efficiently ameliorated the symptoms of colitis. This effect was attributed to the down-regulation of pro-inflammatory cytokines such as Tnf and Il6 in colon-infiltrating monocytes. Down-regulation of pro-inflammatory cytokines by CBt-PMN was also evident in lipopolysaccharide-stimulated bone marrow-derived macrophages (BMDMs). Among many RXR-associated nuclear receptors, activation of peroxisome proliferator-activated receptor δ (PPARδ) and nuclear hormone receptor 77 (Nur77) suppressed cytokine production byAbstract: Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, is an intractable disease of the gastrointestinal tract. Multiple environmental factors, including food ingredients, have been implicated in the development of these diseases. For example, animal fat-rich diets are predisposing factors for ulcerative colitis, whereas n -3 unsaturated fatty acids such as docosahexaenoic acid (DHA) show protective effects in experimental colitis and are negatively correlated with the incidence of ulcerative colitis and Crohn's disease. Given that DHA exhibits agonistic activity on retinoid X receptor (RXR), activation of RXR could be a therapeutic strategy for IBD. However, conventional full RXR agonists are known to show considerable adverse effects. We therefore took advantage of a partial RXR agonist, CBt-PMN, to minimize the adverse effects, and evaluated its efficacy in dextran sodium sulfate-induced colitis. Administration of CBt-PMN efficiently ameliorated the symptoms of colitis. This effect was attributed to the down-regulation of pro-inflammatory cytokines such as Tnf and Il6 in colon-infiltrating monocytes. Down-regulation of pro-inflammatory cytokines by CBt-PMN was also evident in lipopolysaccharide-stimulated bone marrow-derived macrophages (BMDMs). Among many RXR-associated nuclear receptors, activation of peroxisome proliferator-activated receptor δ (PPARδ) and nuclear hormone receptor 77 (Nur77) suppressed cytokine production by BMDMs. These observations suggest that the activation of PPARδ/RXR and Nur77/RXR heterodimers by CBt-PMN through the permissive mechanism is responsible for diminishing the monocyte-mediated inflammatory response in the gut. Our data highlight the importance of RXR activation in the regulation of colitis. Abstract : A partial RXR agonist reduces side-effects while ameliorating colitis … (more)
- Is Part Of:
- International immunology. Volume 31:Number 4(2019)
- Journal:
- International immunology
- Issue:
- Volume 31:Number 4(2019)
- Issue Display:
- Volume 31, Issue 4 (2019)
- Year:
- 2019
- Volume:
- 31
- Issue:
- 4
- Issue Sort Value:
- 2019-0031-0004-0000
- Page Start:
- 251
- Page End:
- 262
- Publication Date:
- 2018-12-26
- Subjects:
- inflammatory bowel disease -- monocytes -- Nur77 -- PPARδ -- RXR
Immunology -- Periodicals
616.079 - Journal URLs:
- http://intimm.oxfordjournals.org/ ↗
http://ukcatalogue.oup.com/ ↗ - DOI:
- 10.1093/intimm/dxy089 ↗
- Languages:
- English
- ISSNs:
- 0953-8178
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4541.038930
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 16297.xml